Research programme: diabetes therapy - NOXXON Pharma AG

Drug Profile

Research programme: diabetes therapy - NOXXON Pharma AG

Alternative Names: NOX-4277; NOX-A42

Latest Information Update: 09 Feb 2011

Price : $50

At a glance

  • Originator NOXXON Pharma AG
  • Class Nucleotide aptamers
  • Mechanism of Action Islet amyloid polypeptide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 24 Jan 2008 This programme is available for licensing (
  • 12 Jul 2005 Preclinical trials in Type-2 diabetes mellitus in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top